A Thorough QT (TQT) Study of CHF5993 pMDI in Healthy Volunteers (HV)
Status:
Recruiting
Trial end date:
2023-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the potential for cardiac repolarization, according
to electrocardiographic monitoring (including QT and QTc intervals), of two dose levels of
CHF5993 pMDI (beclomethasone dipropionate/formoterol fumarate/glycopyrronium bromide
(BDP/FF/GB)) and of one dose of CHF5259 (GB) in healthy subjects compared to moxifloxacin and
placebo.